Warner Chilcott PLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Warner Chilcott PLC
A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.
Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
Deal Snapshot: Ginkgo will earn up to $406m in fees plus royalties as it works with Boehringer Ingelheim to mine its metagenomics database for drug candidates.
- Other Names / Subsidiaries
- Galen Holdings PLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.